arrow
T

Toshiaki Takahashi

Shizuoka Cancer Center
H指数:55
被引数:1.4万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Osimertinib after definitive CRT in unresectable stage III EGFR-mutated NSCLC: safety outcomes from the phase III LAURA study

奥希替尼在不可切除III期EGFR突变非小细胞肺癌中序贯根治性放化疗后的安全性结局:III期LAURA研究

2026-06-060
PREAI
Pharmacokinetics and Bioavailability of Pembrolizumab With Berahyaluronidase Alfa for Subcutaneous Administration in Participants With Advanced or Metastatic Solid Tumors: The Phase 1 Study 3475A-C18

帕博利珠单抗联合重组人透明质酸酶α皮下给药的药代动力学与生物利用度研究:晚期或转移性实体瘤患者I期研究3475A-C18

2025-08-090
PREAI
ADAR1 as a prognostic marker for patients with colorectal cancer and synchronous liver metastasis and a predictor of chemotherapy efficacy

ADAR1作为结直肠癌伴同时性肝转移患者预后的标志物,以及化疗疗效的预测因子

2025-07-230
OAAI
Phase II study of afatinib for advanced non-small cell lung cancer with uncommon epidermal growth factor receptor mutations, including compound mutations detected by next-generation sequencing

II期研究:阿法替尼治疗携带罕见表皮生长因子受体突变(包括由下一代测序检测到的复合突变)的晚期非小细胞肺癌

2025-07-060
PRE
ADAR1-high tumor-associated macrophages induce drug resistance and are therapeutic targets in colorectal cancer

ADAR1高表达的肿瘤相关巨噬细胞诱导药物耐药性,并且是结直肠癌中的治疗靶点。

2025-04-160
OA
A Single-Arm Phase 2 Study of Sotorasib Plus Carboplatin and Pemetrexed in Patients With Advanced Nonsquamous NSCLC With KRAS G12C Mutation (WJOG14821L, SCARLET)

一项索托拉西布联合卡铂和培美曲塞治疗携带KRAS G12C突变、晚期非鳞状NSCLC患者的单臂II期研究(WJOG14821L, SCARLET)

2025-01-170
OAAI
Efficacy of tranilast in preventing exacerbating cardiac function and death from heart failure in muscular dystrophy patients with advanced-stage heart failure: a single-arm, open-label, multicenter study
2025-01-090
OAAI
Predictive marker for response to trifluridine/tipiracil plus bevacizumab in metastatic colorectal cancer patients
2025-01-020
OAAI
A phase II study of ME2136 (Asenapine Maleate) plus standard antiemetic therapy for patients, including diabetic patients, receiving cisplatin-based chemotherapy

ME2136 (马来酸阿塞那平) 加标准止吐治疗的II期研究,用于接受基于顺铂的化疗的患者,包括糖尿病患者

2024-10-260
PRE
Osimertinib after Chemoradiotherapy in Stage III EGFR-Mutated NSCLC

III期EGFR突变的NSCLC放化疗后的奥希替尼

2024-08-1532
PRE
Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study

Amivantamab联合化疗联合或不联合lazertinib治疗奥希替尼治疗EGFR突变晚期NSCLC后疾病进展: III期MARIPOSA-2研究的主要结果

2024-01-01101
OA
Long-term benefit of sotorasib in patients with KRAS G12C-mutated non-small-cell lung cancer: plain language summary

sotorasib对KRAS G12C-mutated非小细胞肺癌患者的长期益处: 简明语言总结

2023-11-271
OA